Risk Factors Update Summary
- Accumulated deficit increased from $239 million to $333 million as of December 31, 2023.
- Net loss increased from $93.8 million in 2022 to $106.9 million in 2023.
- Full-time employees decreased from 180 to 179, with 143 engaged in research and development.
- Cash and cash equivalents decreased from $343 million to $223 million as of December 31, 2023.
- Received a $40 million milestone payment from Roche in February 2024.
- Canadian federal and provincial non-capital loss carry forwards increased from $158 million to $263 million.
- Marketable securities decreased from $9 million to $6 million as of December 31, 2023.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1808158&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.